Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor–induced colitis
Open accessAbstract
Immune checkpoint inhibitors (ICIs) target advanced malignancies with high efficacy but also predispose patients to immune-related adverse events like immune-mediated colitis (IMC). Given the association between gut bacteria with response to ICI therapy and subsequent IMC, fecal microbiota transplantation (FMT) represents a feasible way to manipulate microbial composition in patients, with a potential benefit for IMC. Here, we present a large case series of 12 patients with refractory IMC who underwent FMT from healthy donors as salvage therapy. All 12 patients had grade 3 or 4 ICI-related diarrhea or colitis that failed to respond to standard first-line (corticosteroids) and second-line immunosuppression (infliximab or vedolizumab). Ten patients (83%) achieved symptom improvement after FMT, and three patients (25%) required repeat FMT, two of whom had no subsequent response. At the end of the study, 92% achieved IMC clinical remission. 16 S rRNA sequencing of patient stool samples revealed that compositional differences between FMT donors and patients with IMC before FMT were associated with a complete response after FMT. Comparison of pre- and post-FMT stool samples in patients with complete responses showed significant increases in alpha diversity and increases in the abundances of Collinsella and Bifidobacterium , which were depleted in FMT responders before FMT. Histologically evaluable complete response patients also had decreases in select immune cells , including CD8 + T cells, in the colon after FMT when compared with non-complete response patients ( n = 4). This study validates FMT as an effective treatment strategy for IMC and gives insights into the microbial signatures that may play a critical role in FMT response.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The therapeutic mechanism of FMT appears multifaceted, involving restoration of microbial richness and immune modulation, as evidenced by reductions in CD8+ cytotoxic T cells and shifts in the Treg-to-cytotoxic T cell ratio within affected colonic tissues.
“The therapeutic mechanism of FMT appears multifaceted, involving not only the restoration of microbial richness but also immune modulation, as evidenced by reductions in CD8+ cytotoxic T cells and shifts in the Treg-to–cytotoxic T cell ratio within affected colonic tissues (Halsey et al., 2023).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Halsey et al., 2023
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · see citing works
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 20,966 · see citing works
VSEARCH: a versatile open source tool for metagenomics
(2016) · doi:10.7717/peerj.2584 · Cited by 10,773 · see citing works
Pruesse, E., Quast, C., Knittel, K., Fuchs, B. M., Ludwig, W., Peplies, J., & Glöckner, F. O. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm864 · Cited by 6,682 · see citing works
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · see citing works
Self-citationInteraction between microbiota and immunity in health and disease
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Research · doi:10.1038/s41422-020-0332-7 · Cited by 3,947 · see citing works
The gut microbiota--masters of host development and physiology
Sommer, F., & Bäckhed, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2974 · Cited by 3,681 · see citing works
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · see citing works
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · see citing works
Lozupone, C., Hamady, M., Kelley, S. T., & Knight, R. D. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.01996-06 · Cited by 2,717 · see citing works
Beghini, F., McIver, L. J., Blanco-Míguez, A., Dubois, L., Asnicar, F., Maharjan, S., Mailyan, A., Manghi, P., Scholz, M., Thomas, A. M., et al. (2021) · eLife · doi:10.7554/elife.65088 · Cited by 2,303 · see citing works
Self-citationCommensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251 · see citing works
Taxonomy, Physiology, and Natural Products of Actinobacteria
Barka, E. A., Vatsa, P., Sanchez, L., Vaillant‐Gaveau, N., Jacquard, C., Klenk, H., Clément, C., Ouhdouch, Y., & van Wezel, G. P. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00019-15 · Cited by 2,244 · see citing works
UNOISE2: improved error-correction for Illumina 16S and ITS amplicon sequencingPreprint
Edgar, R. C. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/081257 · Cited by 1,790 · see citing works
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781 · see citing works
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757 · see citing works
Rivière, A., Selak, M., Lantin, D., Leroy, F., & Vuyst, L. D. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00979 · Cited by 1,746 · see citing works
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310 · see citing works
Bifidobacteria and Their Role as Members of the Human Gut Microbiota
O’Callaghan, A. A., & van Sinderen, D. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00925 · Cited by 1,108 · see citing works
Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives
Joossens, M., Huys, G., Cnockaert, M., De Preter, V., Verbeke, K., Rutgeerts, P., Vandamme, P., & Vermeire, S. (2011) · Gut · doi:10.1136/gut.2010.223263 · Cited by 1,063 · see citing works
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · see citing works
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., et al. (2021) · Science · doi:10.1126/science.aaz7015 · Cited by 966 · see citing works
Self-citationMicrobiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883 · see citing works
An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis
Chen, J., Wright, K., Davis, J. M., Jeraldo, P., Marietta, E. V., Murray, J., Nelson, H., Matteson, E. L., & Taneja, V. (2016) · Genome Medicine · doi:10.1186/s13073-016-0299-7 · Cited by 858 · see citing works
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740 · see citing works
Self-citationIpilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642 · see citing works
Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01694-6 · Cited by 515 · see citing works
Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome
Knights, D., Lassen, K. G., & Xavier, R. J. (2013) · Gut · doi:10.1136/gutjnl-2012-303954 · Cited by 468 · see citing works
Comparing bioinformatic pipelines for microbial 16S rRNA amplicon sequencing
Prodan, A., Tremaroli, V., Brolin, H., Zwinderman, A. H., Nieuwdorp, M., & Levin, E. (2020) · PLOS ONE · doi:10.1371/journal.pone.0227434 · Cited by 462 · see citing works
Complex host genetics influence the microbiome in inflammatory bowel disease
Knights, D., Silverberg, M. S., Weersma, R. K., Gevers, D., Dijkstra, G., Huang, H., Tyler, A. D., van Sommeren, S., Imhann, F., Stempak, J. M., et al. (2014) · Genome Medicine · doi:10.1186/s13073-014-0107-1 · Cited by 418 · see citing works
Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels
Alam, M. T., Amos, G. C. A., Murphy, A. R. J., Murch, S., Wellington, E. M. H., & Arasaradnam, R. P. (2020) · Gut Pathogens · doi:10.1186/s13099-019-0341-6 · Cited by 380 · see citing works
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Hailemichael, Y., Johnson, D. H., Abdel‐Wahab, N., Foo, W. C., Bentebibel, S.-E., Daher, M., Haymaker, C., Wani, K., Saberian, C., Ogata, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.004 · Cited by 365 · see citing works
Self-citationCancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
Marthey, L., Mateus, C., Mussini, C., Nachury, M., Nancey, S., Grange, F., Zallot, C., Peyrin‐Biroulet, L., Rahier, J., de Beauregard, M. B., et al. (2016) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv227 · Cited by 341 · see citing works
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217745144 · Cited by 331 · see citing works
Lee, S.-H., Cho, S.-Y., Yoon, Y., Park, C., Sohn, J., Jeong, J.-J., Jeon, B.-N., Jang, M., An, C., Lee, S., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-020-00831-6 · Cited by 325 · see citing works
Gut Microbiota in Cancer Immune Response and Immunotherapy
Zhou, C., Zhou, Y., & Fang, J. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.01.010 · Cited by 303 · see citing works
Sun, S., Luo, L., Liang, W., Yin, Q., Guo, J., Rush, A. M., Lv, Z., Liang, Q., Fischbach, M. A., Sonnenburg, J. L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921223117 · Cited by 277 · see citing works
Systematic review: colitis associated with anti‐ CTLA ‐4 therapy
Gupta, A., Felice, K. M. D., Loftus, E. V., & Khanna, S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13281 · Cited by 274 · see citing works
Adaptive immune education by gut microbiota antigens
Zhao, Q. S., & Elson, C. O. (2018) · Immunology · doi:10.1111/imm.12896 · Cited by 272 · see citing works
Martinez, J. E., Kahana, D. D., Ghuman, S., Wilson, H. P., Wilson, J. B., Kim, S. C. J., Lagishetty, V., Jacobs, J. P., Sinha‐Hikim, A. P., & Friedman, T. C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.667066 · Cited by 233 · see citing works
<i>Bifidobacterium</i> can mitigate intestinal immunopathology in the context of CTLA-4 blockade
Wang, F., Yin, Q., Chen, L., & Davis, M. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712901115 · Cited by 223 · see citing works
Elkrief, A., El Raichani, L., Richard, C., Messaoudene, M., Belkaid, W., Malo, J., Belanger, K., Miller, W., Jamal, R., Letarte, N., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1568812 · Cited by 208 · see citing works
Yang, Y., Chen, M.-K., Yang, B., Huang, X.-J., Zhang, X., He, L., Zhang, J., & Hua, Z. (2015) · Applied and Environmental Microbiology · doi:10.1128/aem.01906-15 · Cited by 203 · see citing works
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
Brahmer, J. R., & Pardoll, D. M. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0078 · Cited by 190 · see citing works
Host-microbial Cross-talk in Inflammatory Bowel Disease
Nagao‐Kitamoto, H., & Kamada, N. (2017) · Immune Network · doi:10.4110/in.2017.17.1.1 · Cited by 179 · see citing works
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179 · see citing works
Linking Gut Microbiota to Colorectal Cancer
Raskov, H., Burcharth, J., & Pommergaard, H. (2017) · Journal of Cancer · doi:10.7150/jca.20497 · Cited by 151 · see citing works
Genus- and species-specific PCR primers for the detection and identification of bifidobacteria.
Matsuki, T., Watanabe, K., & Tanaka, R. (2003) · PubMed · Cited by 105 · see citing works
Abu‐Sbeih, H., Herrera, L. N., Tang, T., Altan, M., Chaftari, A., Okhuysen, P. C., Jenq, R. R., & Wang, Y. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0714-x · Cited by 95 · see citing works
Self-citationProtective and pro-inflammatory roles of intestinal bacteria
Webb, C. R., Koboziev, I., Furr, K. L., & Grisham, M. B. (2016) · Pathophysiology · doi:10.1016/j.pathophys.2016.02.002 · Cited by 94 · see citing works
Secondary causes of inflammatory bowel diseases
Ghouri, Y. A., Tahan, V., & Shen, B. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i28.3998 · Cited by 94 · see citing works
Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors
Thomas, A. S., Ma, W., & Wang, Y. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2031717 · Cited by 90 · see citing works
Self-citationEfficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis
Bishu, S., Melia, J., Sharfman, W. H., Lao, C. D., Fecher, L. A., & Higgins, P. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.10.029 · Cited by 83 · see citing works
Olaisen, M., Flatberg, A., Granlund, A. V. B., Røyset, E. S., Martinsen, T. C., Sandvik, A. K., & Fossmark, R. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa107 · Cited by 77 · see citing works
Basso, P. J., Fonseca, M. T., Bonfá, G., Alves, V. B. F., Sales‐Campos, H., Nardini, V., & Cardoso, C. R. D. B. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20143932 · Cited by 75 · see citing works
Schierová, D., Březina, J., Mrázek, J., Fliegerova, K. O., Kvasnová, S., Bajer, L., & Drastich, P. (2020) · Cells · doi:10.3390/cells9102283 · Cited by 67 · see citing works
Parra, E. R., Ferrufino‐Schmidt, M. C., Tamegnon, A., Zhang, J., Solis, L. M., Jiang, M., Ibarguen, H. P., Haymaker, C., Lee, J. J., Bernatchez, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88156-0 · Cited by 66 · see citing works
Self-citationIntestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Zhou, Y., Medik, Y. B., Patel, B., Zamler, D. B., Chen, S., Chapman, T., Schneider, S. M., Park, E. M., Babcock, R. L., Chrisikos, T. T., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221333 · Cited by 62 · see citing works
Self-citationThe microbiota and immune‐mediated diseases: Opportunities for therapeutic intervention
Fitzgibbon, G., & Mills, K. H. G. (2020) · European Journal of Immunology · doi:10.1002/eji.201948322 · Cited by 57 · see citing works
Byrd, D. A., Chen, J., Vogtmann, E., Hullings, A. G., Song, S. J., Amir, A., Kibriya, M. G., Ahsan, H., Chen, Y., Nelson, H., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224757 · Cited by 35 · see citing works
Galloway-Peña, J., Jenq, R. R., & Shelburne, S. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3173 · Cited by 32 · see citing works
Self-citationAssociation of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response
Zou, F., Abu‐Sbeih, H., Ma, W., Peng, Y., Qiao, W., Wang, J., Shah, A. Y., Oliva, I. C. G., Piha-Paul, S. A., Thompson, J. A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7647 · Cited by 29 · see citing works
Self-citationRapid identification and quantification of Collinsella aerofaciens using PCR
Kageyama, A., Sakamoto, M., & Benno, Y. (2000) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2000.tb08931.x · Cited by 28 · see citing works
Best Practices for Technical Reproducibility Assessment of Multiplex Immunofluorescence
Laberiano-Fernández, C., Ruiz, S. H., Rojas, F. R., & Parra, E. R. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.660202 · Cited by 27 · see citing works
Self-citationImmune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?
Ramamurthy, C., Godwin, J. L., & Borghaei, H. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0476-y · Cited by 14 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [22]Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang Z-D, Abu-Sbeih H, Sanchez CA, Chang C-C, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR, Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat. Med 24, 1804– 1808 (2018). 30420754 PMC6322556
Cited by
Sorted by citations
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Hu, Y., Hu, Q., Li, Y., Lu, L., Xiang, Z., Yin, Z., Kabelitz, D., & Wu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01653-8 · Cited by 395 · see citing works
Fecal microbiota transplantation: current challenges and future landscapes
Yadegar, A., Bar‐Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-22 · Cited by 379 · see citing works
Kim, Y., Kim, G., Kim, S., Cho, B., Kim, S., Do, E., Bae, D., Kim, S., Kweon, M., Song, J. S., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.06.010 · Cited by 211 · see citing works
Gut microbiota shapes cancer immunotherapy responses
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00786-8 · Cited by 166 · see citing works
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Björk, J. R., Bolte, L. A., Maltez Thomas, A., Lee, K. A., Rossi, N., Wind, T. T., Smit, L. M., Armanini, F., Asnicar, F., Blanco-Miguez, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02803-3 · Cited by 156 · see citing works
Self-citationAdvances and prospects of biomarkers for immune checkpoint inhibitors
Yamaguchi, H., Hsu, J.-M., Sun, L., Wang, S., & Hung, M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101621 · Cited by 146 · see citing works
Ballerini, M., Galié, S., Tyagi, P., Catozzi, C., Raji, H., Nabinejad, A., Macandog, A. D. G., Cordiale, A., Slivinschi, B. I., Kugiejko, K. K., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01318-z · Cited by 92 · see citing works
Elkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 92 · see citing works
Lin, A., Xiong, M., Jiang, A., Huang, L., Wong, H. Z. H., Feng, S., Zhang, C., Yu, H., Chen, L., Chi, H., et al. (2025) · iMeta · doi:10.1002/imt2.70070 · Cited by 91 · see citing works
Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation
Sun, J., Song, S., Liu, J., Chen, F., Li, X., & Wu, G. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00678-x · Cited by 72 · see citing works
The role of the gut microbiota in tumor, immunity, and immunotherapy
Xie, Y., & Liu, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410928 · Cited by 70 · see citing works
Engineered natural killer cells for cancer therapy
Biederstädt, A., & Rezvani, K. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.013 · Cited by 59 · see citing works
Novel strategies for modulating the gut microbiome for cancer therapy
Cho, Y. S., Han, K., Xu, J., & Moon, J. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115332 · Cited by 57 · see citing works
Turjeman, S., Rozera, T., Elinav, E., Ianiro, G., & Koren, O. (2025) · Cell · doi:10.1016/j.cell.2025.01.038 · Cited by 57 · see citing works
The tumor microbiome in cancer progression: mechanisms and therapeutic potential
Zhang, W., Xiang, Y., Ren, H., Liu, Y., Wang, Q., Ran, M., Zhou, W., Lu, T., Zheng, X., Qiao, C., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02403-w · Cited by 55 · see citing works
Elkrief, A., Waters, N. R., Smith, N., Dai, A., Slingerland, J., Aleynick, N., Febles, B., Gogia, P., Socci, N. D., Lumish, M., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0498 · Cited by 48 · see citing works
Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug
Mafe, A. N., & Büsselberg, D. (2025) · Biomedicines · doi:10.3390/biomedicines13020422 · Cited by 48 · see citing works
Gao, Y., Tan, Y.-J., & Fang, J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01026-w · Cited by 47 · see citing works
Fernandes, R., Jabbarizadeh, B., Rajeh, A., Hong, M. M. Y., Baines, K. J., Ernst, S., Winquist, E., Ali, A. S., Penny, S. L., Figueredo, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04183-8 · Cited by 47 · see citing works
Lin, A., Huang, L., Jiang, A., Zhu, L., Mou, W., Li, Y., Zhang, C., Liu, Z., Zhang, J., Cheng, Q., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04183-y · Cited by 46 · see citing works
Dissecting mechanisms of fecal microbiota transplantation efficacy in disease
Andary, C. M., Al, K. F., Chmiel, J. A., Gibbons, S., Daisley, B. A., Parvathy, S. N., Vareki, S. M., Bowdish, D. M. E., Silverman, M., & Burton, J. P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.12.005 · Cited by 45 · see citing works
Mullish, B. H., Merrick, B., Quraishi, M. N., Bak, A., Green, C., Moore, D., Porter, R. J., Elumogo, N., Segal, J. P., Sharma, N., et al. (2024) · Journal of Hospital Infection · doi:10.1016/j.jhin.2024.03.001 · Cited by 41 · see citing works
Wekking, D., van den Ende, T., Bijlsma, M. F., Vidal-Itriago, A., Nieuwdorp, M., & van Laarhoven, H. W. M. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103025 · Cited by 41 · see citing works
Pharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy
Bolte, L. A., Björk, J. R., Gaćeša, R., & Weersma, R. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.04.025 · Cited by 39 · see citing works
Lu, Y., Yuan, H., Liang, S., Li, D., Jiang, P., Wang, X., Zhang, K., & Liu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603658 · Cited by 38 · see citing works
Mullish, B. H., Merrick, B., Quraishi, M. N., Bak, A., Green, C., Moore, D., Porter, R. J., Elumogo, N., Segal, J. P., Sharma, N., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-331550 · Cited by 35 · see citing works
Allegretti, J. R., Khanna, S., Mullish, B. H., & Feuerstadt, P. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.05.004 · Cited by 34 · see citing works
The bacterial microbiome and cancer: development, diagnosis, treatment, and future directions
Qasem, H., & El-Sayed, W. M. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01523-9 · Cited by 34 · see citing works
Elkrief, A., Routy, B., Derosa, L., Bolte, L. A., Wargo, J. A., McQuade, J. L., & Zitvogel, L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-472902 · Cited by 34 · see citing works
A review of engraftment assessments following fecal microbiota transplant
Herman, C., Barker, B. M., Bartelli, T. F., Chandra, V., Krajmalnik‐Brown, R., Jewell, M., Li, L., Liao, C., McAllister, F. M., Nirmalkar, K., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2525478 · Cited by 33 · see citing works
Gut microbiome and immune checkpoint inhibitor toxicity
Verheijden, R. J., van Eijs, M. J. M., Paganelli, F. L., Viveen, M. C., Rogers, M. R. C., Top, J., May, A. M., van de Wijgert, J. H. H. M., & Suijkerbuijk, K. P. M. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115221 · Cited by 32 · see citing works
Otto, L., Strehle, L. D., Loman, B. R., Seng, M. M., Sardesai, S. D., Williams, N. O., Gatti-Mays, M. E., Stover, D. G., Sudheendra, P. K., Wesolowski, R., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00707-6 · Cited by 28 · see citing works
Jing, L., Lv, L., Zhong, L., Xu, F., Su, W., Chen, Y., Wu, Z., He, S., & Chen, Y. (2024) · Advanced Science · doi:10.1002/advs.202413128 · Cited by 27 · see citing works
Gut microbiota in women: The secret of psychological and physical well-being
Marano, G., Traversi, G., Gaetani, E., Gasbarrini, A., & Mazza, M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i45.5945 · Cited by 26 · see citing works
Zhang, X., Li, Y., Guo, Y., Sun, J., & Yang, Y. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1656969 · Cited by 24 · see citing works
Zhang, F., Kamm, M. A., Wu, X., Kao, D. H., Borody, T. J., Chen, L. A., He, X., Fischer, M., Wong, S. H., Ng, S. C., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16947 · Cited by 22 · see citing works
Wang, W., Yu, Y., Wang, R., Wang, Y., Ding, X., Lu, G., Chen, L., Liang, C., Zhang, S., Yi, B., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-335230 · Cited by 22 · see citing works
Self-citationLong-Term Toxicities of Immune Checkpoint Inhibitors
Abraham, P. E., & Johnson, D. B. (2025) · Drugs · doi:10.1007/s40265-025-02243-4 · Cited by 22 · see citing works
The gut microbiome modulate response to immunotherapy in cancer
Jiang, S., Kang, Z., Chen, Y., & Fang, J. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2634-7 · Cited by 20 · see citing works
Microbiota-centered interventions to boost immune checkpoint blockade therapies
Almonte, A. A., Thomas, S., & Zitvogel, L. (2025) · Journal of Experimental Medicine · doi:10.1084/jem.20250378 · Cited by 19 · see citing works
Autoimmune-related adverse events induced by immune checkpoint inhibitors
Sun, Y., Zhang, Z., Jia, K., Liu, H., & Zhang, F. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102556 · Cited by 18 · see citing works
Harvey, C., Nahar, K. J., McKeown, J., Lo, S., Farag, S., Yousaf, N., Young, K., Tas, L., Meerveld-Eggink, A., Blank, C. U., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008232 · Cited by 18 · see citing works
Self-citationThe role of the gut microbiome in modulating immunotherapy efficacy in colorectal cancer
Zuo, S., Huang, Y., & Zou, J. (2024) · IUBMB Life · doi:10.1002/iub.2908 · Cited by 18 · see citing works
Nutrient acquisition of gut microbiota: Implications for tumor immunity
Wang, Y., Huang, J., Tong, H., Jiang, Y., Yu, J., & Ma, X. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.003 · Cited by 18 · see citing works
Self-citationMicrobial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity
Hillege, L. E., Trepka, K. R., Guthrie, B. G. H., Fu, X., Aarnoutse, R., Paymar, M. R., Olson, C., Zhang, C., Ortega, E. F., Ramirez, L., et al. (2025) · mBio · doi:10.1128/mbio.00930-25 · Cited by 17 · see citing works
Multi‐level insights into the immuno‐oncology‐microbiome axis: From biotechnology to novel therapies
Pi, Z., Liu, W. L., Song, C., Zhu, C., Liu, J., Wang, L., Zhao, H., Yang, C., Wu, L., Liu, T., et al. (2024) · iMeta · doi:10.1002/imt2.240 · Cited by 17 · see citing works
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
Shang, J., Valle, D. M. D., Britton, G. J., Mead, K., Rajpal, U., Chen-Liaw, A., Mogno, I., Li, Z., Menon, R., Gonzalez‐Kozlova, E., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232079 · Cited by 16 · see citing works
Guo, H., Cui, J., Li, Q., Liang, X., Li, J., Yang, B., Kalds, P., Chen, Y., & Yang, Y. (2024) · mSystems · doi:10.1128/msystems.00953-23 · Cited by 16 · see citing works
Zhou, Z., Lv, Y., Zuo, A., Zhu, X., Xu, Y., Zuo, L., Xu, H., Liu, S., Zhang, Y., Weng, S., et al. (2025) · hLife · doi:10.1016/j.hlife.2025.05.008 · Cited by 15 · see citing works
Rashidi, A., Ebadi, M., Rehman, T. U., Elhusseini, H., Kazadi, D., Halaweish, H., Khan, M. H., Hoeschen, A. L., Cao, Q., Luo, X., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0138 · Cited by 15 · see citing works
Meng, Y., Sun, J. Y., & Zhang, G. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104403 · Cited by 15 · see citing works
Ecological management of the microbiota in patients with cancer
Xavier, J. B. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01049-3 · Cited by 14 · see citing works
Yi, D., Li, T., Xiao, Y., Zhang, X., Hao, Q., Zhang, F., Qiu, T., Yang, G., Sun, X., Dong, Y., et al. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10728 · Cited by 13 · see citing works
Wang, F., Chen, W., Jia, Y., He, T., Wu, S., Xiang, J., Chen, R., Jiang, Q., Yu, T., Lan, Y., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70994 · Cited by 12 · see citing works
Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma
Jang, A., Lichterman, J. N., Zhong, J. Y., Shoag, J. E., Garcia, J. A., Zhang, T., & Barata, P. C. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2276629 · Cited by 12 · see citing works
Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities
Lee, J. B., Huang, Y., Oya, Y., Nützinger, J., Ang, Y. L. E., Sooi, K. W. X., Cho, B. C., & Soo, R. A. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107862 · Cited by 11 · see citing works
Ye, Z.-N., Eslick, G. D., Huang, S., & He, X. (2024) · eGastroenterology · doi:10.1136/egastro-2024-100099 · Cited by 11 · see citing works
Machado, A. P., Shaikh, A. S., Saji, A., Shatila, M., Oliva, I. G., Wang, Y., & Thomas, A. S. (2024) · Cancers · doi:10.3390/cancers16101919 · Cited by 11 · see citing works
Self-citationFatima, S. N., Arif, F., Khalid, R., Khan, M., & Naseem, K. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107882 · Cited by 10 · see citing works
Host-microbiota interactions in genitourinary cancer immunotherapy
Xu, X., Cui, J., Li, W., Xu, Y., Yuan, S., Zeng, X., & Li, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.07.005 · Cited by 10 · see citing works
Tang, Z., Shi, J., Xu, S., Liu, S., Yin, W., Xiang, Y., Li, J., He, Z., Yao, X., Zhou, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011959 · Cited by 10 · see citing works
Microbiome dysbiosis and chemotherapy resistance in acute myeloid leukemia (AML)
Tian, M., Samarkhazan, H. S., Alemohammad, S. S., Fakhraei, M., Tavakoli, F., Shams, A., & Zeynalabadi, A. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00891-8 · Cited by 9 · see citing works
Nanjing Consensus II on Washed Microbiota Transplantation: Statements From the CHINAGUT Conference
Zhang, F., Wong, H. S., Lu, G., Pi, Z., Zhang, T., Yu, H. H., Bu, N., Chen, X., Cui, B., Dafa, D., et al. (2026) · Microbiota Medicine Research · doi:10.1002/mmr3.70006 · Cited by 9 · see citing works
Hu, J., Chen, H., Zhu, L., Tong, Y., Cheng, C., Yan, G., & Shen, H. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01143-9 · Cited by 8 · see citing works
Ye, R., Zheng, H., Yang, D., Lin, J., Li, L., Li, Y., Pan, H., Dai, H., Zhao, L., Zhou, Y., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116999 · Cited by 8 · see citing works
The skin microbiome in dermatologic disease
MacGibeny, M. A., Adjei, S., Pyle, H. J., Bunick, C. G., Ghannoum, M. A., Grada, A. A., Harris-Tryon, T. A., Tyring, S. K., & Kong, H. H. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.07.1499 · Cited by 7 · see citing works
Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy
Hu, J., Feng, T., Zhang, L., Zhou, Q., & Zhu, L. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003687 · Cited by 7 · see citing works
Lucia, S. S. D., Nista, E. C., Candelli, M., Archilei, S., Deutschbein, F., Capuano, E., Gasbarrini, A., Franceschi, F., & Pignataro, G. (2025) · Cancers · doi:10.3390/cancers17223618 · Cited by 7 · see citing works
The Gut–Brain–Immune Axis in Glioma: Emerging Mechanisms and Therapeutic Opportunities
Feng, R., Yang, Z., Zhou, Y., & Zhao, H. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01680-3 · Cited by 7 · see citing works
Cruz, C. C., Santos, M. J. M. N., Wali, S., Varatharajalu, K., Thomas, A. S., & Wang, Y. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2473305 · Cited by 7 · see citing works
Self-citationGao, Y., Shahbaz, S., Elahi, S., Monaghan, T. M., LFMT vs LSFF Consortium, & Kao, D. H. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2620127 · Cited by 6 · see citing works
Microbiota and immune-related adverse events in cancer immunotherapy
Schneider, S. M., Fan, C., Wang, Y., Jenq, R. R., & Watowich, S. S. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00921-3 · Cited by 6 · see citing works
Self-citationNew strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis
Velikova, T. V., Krastev, B. M., Gulinac, M., Zashev, M., Graklanov, V., & Peruhova, M. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i6.1050 · Cited by 6 · see citing works
Gastrointestinal toxicities of proteasome inhibitor therapy
Shah, J., Devalaraju, S. S., Baerman, E. A., Lee, I. J.-A., Takigawa, K., Machado, A. P., Catinis, C., Shatila, M., Varatharajalu, K., Shafi, M. A., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05716-3 · Cited by 6 · see citing works
Self-citationJustice, J. B., Kankaria, R. A., & Johnson, D. B. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2431513 · Cited by 6 · see citing works
Hearn, J., Malik, G., Stukalin, I., Panaccione, R., Ingram, R. J. M., & Ma, C. (2025) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001847 · Cited by 6 · see citing works
Severe Allergy as a Chronic Inflammatory Condition From a Systems Biology Perspective
Dolset, M. I. D., Pablo‐Torres, C., Contreras, N., Couto-Rodriguez, A., Escolar‐Peña, A., Graña‐Castro, O., Izquierdo, E., López‐Rodríguez, J. C., Macías‐Camero, A., Pérez‐Gordo, M., et al. (2024) · Clinical & Experimental Allergy · doi:10.1111/cea.14517 · Cited by 6 · see citing works
Li, C., Zhao, L., Wang, X., Wu, J., Chen, H., & Lü, Q. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04209-4 · Cited by 5 · see citing works
Hu, X., Ma, C., & Kong, X. (2024) · Cancer Screening and Prevention · doi:10.14218/csp.2024.00017 · Cited by 5 · see citing works
Wu, Y., Li, S., Liu, L., Zhang, X., Lv, J., Li, Q., & Li, Y. (2024) · Journal of Pediatric Surgery Open · doi:10.1016/j.yjpso.2024.100134 · Cited by 4 · see citing works
Mei, R., Pepe, E., Oh, D. Y., Tsai, K. K., Chugh, R., & Kattah, M. G. (2024) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izae259 · Cited by 4 · see citing works
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy
Braun, L. M., Lu, Y., & Zeiser, R. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.07.005 · Cited by 4 · see citing works
Golčić, M., Radoš, L., Skočilić, I., Badovinac, I., Hauser, G., Zrnić, I. K., Šantić, M., Čupić, D. F., Francetić, S., Lisica, K., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18111719 · Cited by 4 · see citing works
Microbiome-modulated immunotherapy in oncology: Current applications and future prospects
Liu, Y., Miao, K., & Yang, X. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.01.001 · Cited by 4 · see citing works
Zhang, F., Hu, K., Sun, C., Chen, R., Ni, G., Liu, X., Wei, L., & Su, R. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2662690 · Cited by 4 · see citing works
Advances and challenges in microbiome transplantation
Sen, P., Kaulmann, D., Youngster, I., Abdeen, S. K., & Elinav, E. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.06.006 · Cited by 4 · see citing works
Ninkov, M., & Vareki, S. M. (2026) · Nature Communications · doi:10.1038/s41467-026-76051-z · Cited by 4 · see citing works
Microbiome dynamics in immune checkpoint blockade
Kim, C. W., Kim, H.-J., & Lee, H. K. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.013 · Cited by 4 · see citing works
Ma, B.-T., Sang, L.-X., & Chang, B. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i24.3123 · Cited by 4 · see citing works
Assessing live microbial therapeutic transmission
Faith, J. J. (2025) · Gut Microbes · doi:10.1080/19490976.2024.2447836 · Cited by 4 · see citing works
Microbiota Manipulation as an Emerging Concept in Cancer Therapy
Spalinger, M. R., & Scharl, M. M. (2023) · Visceral Medicine · doi:10.1159/000534810 · Cited by 4 · see citing works
Kim, H., Shin, Y. E., Yoo, H.-J., Kim, J. Y., Yoo, J., Kim, S. G., & Kim, Y. S. (2024) · Medicina · doi:10.3390/medicina60091422 · Cited by 4 · see citing works
The role of the microbiome in immune checkpoint inhibitor colitis and hepatitis
Ryan, T., Ling, S., Trinh, A., & Segal, J. P. (2024) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2024.101945 · Cited by 3 · see citing works
RFW captures species-level metagenomic functions by integrating genome annotation information
Mi, K., Xu, R., & Liu, X. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100932 · Cited by 3 · see citing works
GAUDIO, A. D., Lopetuso, L. R., Pavese, V., Palesandro, E., Campisi, I., Tucci, M., & Scaldaferri, F. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251358174 · Cited by 3 · see citing works
Chen, Y., Wang, Z., Zeng, Y., Xie, X., Liu, L., & Qian, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1708826 · Cited by 3 · see citing works
Han, W., Li, Q., & Yuan, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1802676 · Cited by 3 · see citing works
Elsheikh, M., Ibrahim, M. A., Fares, S., Bhongade, M., Adhem, K., Ramirez-Morales, X. I., Kaseb, A. O., Petrosino, J. F., Hassan, M. M., & Jalal, P. K. (2026) · Cancer Medicine · doi:10.1002/cam4.71738 · Cited by 3 · see citing works
Liu, J., Zhao, P., Jiang, D., Li, S. B., Jin, C., Xu, D., Wang, X. M., Chen, Y., Tang, B., & Qu, X. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2672791 · Cited by 3 · see citing works
Alexander, J. B., Mullish, B. H., Thomas, L., Weersma, R. K., Sokol, H., Roberts, L. A., Edwards, L. A., Emmanuel, A. V., Gerasimidis, K., Hall, L. J., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-338252 · Cited by 3 · see citing works
- Authors
- Halsey, T. M., Thomas, A. S., Hayase, T., Ma, W., Abu-Sbeih, H., Sun, B., Parra, E. R., Jiang, Z.-D., DuPont, H. L., Sanchez, C., El-Himri, R., Brown, A., Flores, I., McDaniel, L., Ortega Turrubiates, M., Hensel, M., Pham, D., Watowich, S. S., Hayase, E., Chang, C.-C., Jenq, R. R., & Wang, Y.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
- Center for Infectious Diseases, School of Public Health, University of Texas, Houston, TX 77054, USA.
- Kelsey Research Foundation (US)
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
- Middlebury College (US)
- Corresponding author
- Halsey, Taylor M.
- Thomas, Anusha S.
- Jenq, Robert R.
- Wang, Yinghong
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2023-06-14
- Volume
- 15
- Issue
- 700
- Pages
- eabq4006-eabq4006
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC10759507
- OpenAlex
- W4380590697
- Cited by
- 161
- References
- 66
- Citations by year
- 2026: 54 · 2025: 55 · 2024: 47 · 2023: 5
- FWCI
- 19.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Science Translational Medicine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- Cancer Prevention and Research Institute of Texas (RP210042)
- Seres Therapeutics
- University of Texas MD Anderson Cancer Center
- National Heart, Lung, and Blood Institute (R01HL124112)
- National Cancer Institute (P30CA016672)
- Moonshot Research and Development Program
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Keywords
- fecal microbiota transplantation, immune checkpoint inhibitors, immune-related colitis, immune-related adverse events, refractory colitis, gut microbiota, microbial signatures, Collinsella, Bifidobacterium, alpha diversity, CD8+ T cells, immunosuppressive therapy
- MeSH terms
- Fecal Microbiota Transplantation, Immune Checkpoint Inhibitors, Aged, Colitis, Feces, Female, Humans, Male, Middle Aged, RNA, Ribosomal, 16S
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
